J Korean Neurosurg Soc.
2025 May;68(3):305-310. 10.3340/jkns.2025.0050.
Li-Fraumeni Syndrome : Current Strategies and Future Perspectives
- Affiliations
-
- 1Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- KMID: 2567462
- DOI: http://doi.org/10.3340/jkns.2025.0050
Abstract
- Li-Fraumeni syndrome (LFS) is a rare inherited cancer predisposition syndrome caused by germline mutations in the TP53 tumor suppressor gene. It predisposes affected individuals to a wide spectrum of early-onset malignancies, including sarcomas, breast cancer, brain tumors, and adrenocortical carcinoma. Advances in genetic testing and risk management strategies have enhanced the identification and clinical management of LFS patients. Comprehensive surveillance has demonstrated increased survival rates through proactive screening. Beyond surveillance, research is exploring novel approaches such as liquid biopsy for early cancer detection and chemoprevention strategies, including metformin trials, to mitigate cancer risk. This review discusses the molecular basis, clinical spectrum, surveillance strategies, and emerging research in LFS.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Breast Cancer after Radiation Therapy in a Patient with Li-Fraumeni Syndrome: A Case Report
- Osteosarcoma with Adenocarcinoma of Lung in Li-Fraumeni Syndrome: A Case Report
- Family of Li-Fraumeni Syndrome with a Germline Mutation in the p53 Gene
- The first documentation of Li-Fraumeni syndrome in Korea
- A Case of Late-Onset Li-Fraumeni-like Syndrome with Unilateral Breast Cancer
